Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma.
Huang CY et al.
Bmc Cancer, 2025
Shared neoantigens' atlas for off-the-shelf cancer vaccine development.
Mauriello A et al.
Journal of Translational Medicine, 2025
Exploring the Genetic and Clinical Landscape of Dedifferentiated Endometrioid Carcinoma.
Haraga H et al.
International Journal of Molecular Sciences, 2025
Lack of dominant-negative activity for tumor-related ZNRF3 missense mutations at endogenous levels.
Li S et al.
Oncogene, 2025
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies.
Veas Rodriguez J et al.
Journal for Immunotherapy of Cancer, 2025
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival.
Varghese AM et al.
Nature Medicine, 2025
Define a good prognosis of RNF43 codon 659-mutated and concomitant genomic signatures in CRC: an analysis of the cBioPortal database.
Wang F et al.
Frontiers in Oncology, 2025
Loss of ZNRF3/RNF43 Unleashes EGFR in Cancer.
Yue F et al.
Biorxiv : the Preprint Server for Biology, 2024
RNF43 and ZNRF3: Versatile regulators at the membrane and their role in cancer.
Li S et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2024
Predicting T cell receptor functionality against mutant epitopes.
Drost F et al.
Cell Genomics, 2024
Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features.
Wijetunga NA et al.
Cancer Research Communications, 2024
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Prognostic genome and transcriptome signatures in colorectal cancers.
Nunes L et al.
Nature, 2024
RNF43 in cancer: Molecular understanding and clinical significance in immunotherapy.
Huo X et al.
The Journal of Gene Medicine, 2024
Molecular profiling of pediatric and young adult colorectal cancer reveals a distinct genomic landscapes and potential therapeutic avenues.
Busico A et al.
Scientific Reports, 2024
Unravelling the role of PLK1 in tumorigenesis by revealing the mutational landscape of colorectal and lung cancer with PLK1 mutations.
Wang S et al.
Journal of Cellular and Molecular Medicine, 2024
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X et al.
Bmc Medicine, 2024
Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas.
Pu X et al.
Cell & Bioscience, 2023
Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome.
Yang LP et al.
Cell Reports. Medicine, 2023
Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y et al.
European Journal of Medical Research, 2023
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
Liu Y et al.
Cancer Research, 2023
Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors.
Kim M et al.
Cancer Research and Treatment, 2023
RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer.
Shang P et al.
Frontiers in Oncology, 2023
Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment.
Shao X et al.
Frontiers in Oncology, 2023
Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China.
Zhang H et al.
Frontiers in Oncology, 2023
RNF43 mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
Huang K et al.
American Journal of Cancer Research, 2023
Phenotypic plasticity and genetic control in colorectal cancer evolution.
Househam J et al.
Nature, 2022
Metabolic balance in colorectal cancer is maintained by optimal Wnt signaling levels.
Imkeller K et al.
Molecular Systems Biology, 2022
NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.
Wang H et al.
Cancer Medicine, 2022
RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition.
Fang L et al.
Nature Communications, 2022
The earliest events in BRAF-mutant colorectal cancer: exome sequencing of sessile serrated lesions with a tiny focus dysplasia or cancer reveals recurring mutations in two distinct progression pathways.
Bleijenberg AG et al.
The Journal of Pathology, 2022
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.
Seeber A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
Yamamoto D et al.
The Journal of Pathology, 2022
The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y et al.
Bmc Cancer, 2022
Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses.
Kim SC et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2022
Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets.
Karagiannakos A et al.
Cancers, 2022
Comprehensive genomic profiling of colorectal cancer patients reveals differences in mutational landscapes among clinical and pathological subgroups.
Li P et al.
Frontiers in Oncology, 2022
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
Nguyen HT et al.
Frontiers in Oncology, 2022
Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancers.
Grant A et al.
Scientific Reports, 2021